Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabina Signoretti

Showing results (141-150 of 257) with videos related to

Pageof 26
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2021
<i>BRCA1/Trp53</i> heterozygosity and replication stress drive esophageal cancer development in a mouse modelYe He, Joshua Rivera, Miklos Diossy, et al.
Cell Reports. Medicine|September 20, 2023
Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer statesJackson Nyman, Thomas Denize, Ziad Bakouny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2019
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUNAbdallah Flaifel, Wanling Xie, David A Braun, et al.
British Journal of Cancer|April 21, 2018
Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinomaGuillermo de Velasco, Stephanie A Wankowicz, Russell Madison, et al.
The Oncologist|February 22, 2017
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic ModelGuillermo de Velasco, Aedín C Culhane, André P Fay, et al.
Cancer Immunology, Immunotherapy : CII|October 4, 2016
Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2Wei Wang, Amy K Erbe, Mikayla Gallenberger, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer statesJackson Nyman, Thomas Denize, Ziad Bakouny, et al.
Nature Communications|August 25, 2022
Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1Hsiao-Yun Chen, Yavuz T Durmaz, Yixiang Li, et al.
Journal for Immunotherapy of Cancer|March 23, 2026
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0Rana R McKay, Archana Ajmera, Michael B Atkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2016
FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell CarcinomaAmy K Erbe, Wei Wang, Jacob Goldberg, et al.
Pageof 26

Showing results (141-150 of 257) with videos related to

Sort By:
Pageof 26
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2021
<i>BRCA1/Trp53</i> heterozygosity and replication stress drive esophageal cancer development in a mouse modelYe He, Joshua Rivera, Miklos Diossy, et al.
Cell Reports. Medicine|September 20, 2023
Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer statesJackson Nyman, Thomas Denize, Ziad Bakouny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2019
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUNAbdallah Flaifel, Wanling Xie, David A Braun, et al.
British Journal of Cancer|April 21, 2018
Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinomaGuillermo de Velasco, Stephanie A Wankowicz, Russell Madison, et al.
The Oncologist|February 22, 2017
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic ModelGuillermo de Velasco, Aedín C Culhane, André P Fay, et al.
Cancer Immunology, Immunotherapy : CII|October 4, 2016
Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2Wei Wang, Amy K Erbe, Mikayla Gallenberger, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer statesJackson Nyman, Thomas Denize, Ziad Bakouny, et al.
Nature Communications|August 25, 2022
Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1Hsiao-Yun Chen, Yavuz T Durmaz, Yixiang Li, et al.
Journal for Immunotherapy of Cancer|March 23, 2026
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0Rana R McKay, Archana Ajmera, Michael B Atkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2016
FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell CarcinomaAmy K Erbe, Wei Wang, Jacob Goldberg, et al.
Pageof 26